Chronic atrial and intestinal dysrhythmia
|
0.720 |
GeneticVariation
|
disease |
BEFREE |
A new study identifies homozygous missense mutations in SGOL1, which encodes a component of the cohesin complex, in a newly described disorder termed Chronic Atrial and Intestinal Dysrhythmia (CAID) syndrome.
|
25352100 |
2014 |
Chronic atrial and intestinal dysrhythmia
|
0.720 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Our findings identify CAID syndrome as a novel generalized dysrhythmia, suggesting a new role for SGOL1 and the cohesin complex in mediating the integrity of human cardiac and gut rhythm.
|
25282101 |
2014 |
Chronic atrial and intestinal dysrhythmia
|
0.720 |
Biomarker
|
disease |
BEFREE |
Morpholino-induced knockdown of sgol1 in zebrafish recapitulated the abnormalities seen in humans with CAID syndrome.
|
25282101 |
2014 |
Chronic atrial and intestinal dysrhythmia
|
0.720 |
GermlineCausalMutation
|
disease |
ORPHANET |
Our findings identify CAID syndrome as a novel generalized dysrhythmia, suggesting a new role for SGOL1 and the cohesin complex in mediating the integrity of human cardiac and gut rhythm.
|
25282101 |
2014 |
Chronic atrial and intestinal dysrhythmia
|
0.720 |
GeneticVariation
|
disease |
UNIPROT |
Our findings identify CAID syndrome as a novel generalized dysrhythmia, suggesting a new role for SGOL1 and the cohesin complex in mediating the integrity of human cardiac and gut rhythm.
|
25282101 |
2014 |
Chronic atrial and intestinal dysrhythmia
|
0.720 |
Biomarker
|
disease |
CTD_human |
|
|
|
Chronic atrial and intestinal dysrhythmia
|
0.720 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
Cardiac Arrhythmia
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Our findings identify CAID syndrome as a novel generalized dysrhythmia, suggesting a new role for SGOL1 and the cohesin complex in mediating the integrity of human cardiac and gut rhythm.
|
25282101 |
2014 |
Intestinal Diseases
|
0.300 |
Biomarker
|
group |
CTD_human |
Mutations in SGOL1 cause a novel cohesinopathy affecting heart and gut rhythm.
|
25282101 |
2014 |
Chronobiology Disorders
|
0.300 |
Biomarker
|
group |
CTD_human |
Mutations in SGOL1 cause a novel cohesinopathy affecting heart and gut rhythm.
|
25282101 |
2014 |
Circadian Rhythm Disorders
|
0.300 |
Biomarker
|
disease |
CTD_human |
Mutations in SGOL1 cause a novel cohesinopathy affecting heart and gut rhythm.
|
25282101 |
2014 |
Psychogenic Inversion of Circadian Rhythm
|
0.300 |
Biomarker
|
disease |
CTD_human |
Mutations in SGOL1 cause a novel cohesinopathy affecting heart and gut rhythm.
|
25282101 |
2014 |
Failure to Thrive
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Sick Sinus Syndrome
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Bradycardia
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Carcinogenesis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Antagonizing pathways leading to differential dynamics in colon carcinogenesis in Shugoshin1 (Sgo1)-haploinsufficient chromosome instability model.
|
25773652 |
2016 |
Carcinogenesis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Tumor-promoting/progressing role of additional chromosome instability in hepatic carcinogenesis in Sgo1 (Shugoshin 1) haploinsufficient mice.
|
25740822 |
2015 |
Carcinogenesis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Shugoshin1 (SGO1) is an important player in appropriate chromosome segregation and is involved in tumorigenesis.
|
23564482 |
2013 |
Carcinogenesis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Recent studies have identified shugoshin (SGO-1) as an important player in proper chromosome segregation and the involvement in tumorigenesis.
|
22161216 |
2012 |
Liver carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Further, loss of SGOL1 from HCC cell decreased the cytotoxicity of sorafenib in vivo.
|
29467456 |
2018 |
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
We propose that formation of ACF in Sgo1(-/+) mice is facilitated by the IL6-STAT3-SOCS3 oncogenic pathway and by the Bcl2-anti-apoptotic pathway, yet further development of the ACF to tumors is inhibited by the p16(INK4A) tumor suppressor pathway.
|
25773652 |
2016 |
Liver carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Treatment with the carcinogen azoxymethane caused Sgo1(-/+) ME-CIN model mice to develop HCCs within 6 months, whereas control mice developed no HCC (P < 0.003).
|
25740822 |
2015 |
Liver carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Together, these results highlight the essential role of Sgo1 in the maintenance of a proper mitotic progression in hepatoma cells and suggest that Sgo1 is a promising oncotarget for HCC.
|
25638162 |
2015 |
Colorectal Carcinoma
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to explore whether SGOL1 and PDS5B genes are mutated and expressionally altered in gastric and colorectal cancers.
|
23850494 |
2013 |
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Both SGOL1 and PDS5B are considered putative tumor suppressor genes.
|
23850494 |
2013 |